Sanofi: positive results in bullous pemphigoid

(CercleFinance.com) - Sanofi reports that positive results from the pivotal Phase II/III ADEPT study evaluating its Dupixent for the treatment of moderate to severe adult bullous pemphigoid were presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting.


Sanofi says that Bullous pemphigoid is a chronic, disabling, recurrent skin disease with underlying type 2 inflammation, characterized by intense itching, blistering, red patches and painful lesions.

According to the study's results, five times as many adults treated with Dupixent showed sustained remission at week 36, compared with placebo; significant reductions in disease severity and itching were also observed.

Dupixent also significantly reduced the need for oral corticosteroids or rescue medication, compared with placebo. Regulatory submissions are currently under review by US and EU regulatory authorities.


Copyright (c) 2025 CercleFinance.com. All rights reserved.